icon-nav-help
Need Help

Submit your question to our team of health care professionals.

icon-nav-current-questions
Current Question

See what's on the mind of the community right now.

icon-conf-speakers-at-a-glance
Meet the Team

Learn more about our world-renowned team.

icon-nav-archives
CWD Answers Archives

Review the entire archive according to the date it was posted.

CWD_Answers_Icon
March 17, 2003

Blood Tests and Insulin Injections, Insulin Pumps

advertisement
Question from Columbus, Georgia, USA:

Before starting a pump with NovoLog, my daughter developed lipoatrophy on the right side of her naval. After switching to the pump, we were advised to begin switching sides, keeping away from the atrophied area, as well as spacing the infusion sites in a clock pattern for extra precaution. Since then, she has developed another lipoatrophy site above the older one (even though we stayed clear of the first one) and very recently has shown the beginnings of another site right above the other two sites at her first rib. This last site had no pump infusion sites remotely near it, yet it continues to develop.

Even though we swap sides and change sites regularly, her doctor seems to think that her problem stems from her being right handed and is using more force on that side when using her infusion injection device. We feel that it is not the case since she always uses both hands to release the infusion injector buttons, not just one. This would not explain the fact that there is another site developing right at her rib cage. We’re even advising our daughter to move her infusion site around to the back side of her waist where adults have their “spare tires” to keep a longer rotation of the infusion needle. Is there another explanation for these “dents”? Is this so new that it hasn’t been fully explored yet?

Answer:

From: DTeam Staff

I have not had to deal with lipoatrophy in a long time. Maybe she is particularly vulnerable to it. I don’t have the same experience with NovoLog in other patients, but it is new enough that the data base is smaller than other rapid insulins particularly regarding lipoatrophy.

LD